Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig plus pomalidomide versus standard available therapies in relapsed or refractory multiple myeloma
jRCT2021260046Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2026
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of etentamig and pomalidomide in multiple myeloma (MM) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants with adverse events, Complete response or better rate and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
etentamigpomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2021260046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260046.